Kidney Cancer Coverage from Every Angle
Advertisement
Advertisement

Sumanta K. Pal, MD, on Clinical Implications of SWOG 1500 Trial of Cabozantinib for Papillary Kidney Cancer

Posted: Saturday, March 6, 2021

Sumanta K. Pal, MD, of City of Hope, discusses the SWOG 1500 study, which demonstrated the effectiveness of cabozantinib vs sunitinib in prolonging progression-free survival, whether this might be practice-changing, and what clinicians should consider when it comes to selecting treatment for patients with metastatic papillary renal cell carcinoma.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.